| |
|
A WEEK-IN-REVIEW FEATURED REPORT
Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of
Combination Regimens for
Initial Treatment of HIV: Final Results.
Sax PE, Tierney C, Collier
AC, et al
J Infect Dis. 2011
Oct;204(8):1191-1201.
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
Abacavir and lamivudine for the treatment of human
immunodeficiency virus.
Rizzardini G, Zucchi P.
Expert Opin Pharmacother.
2011 Sep;12(13):2129-38
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
Comparison of abacavir/lamivudine and
tenofovir/emtricitabine among treatment-naïve
HIV-infected patients initiating therapy.
Tan DH, Chan K, Raboud J, Cooper C, et al
J Acquir Immune Defic Syndr.
2011 Jun 24.
Abstract
Peripheral and Central Fat Changes in Subjects Randomized to
Abacavir-Lamivudine or
Tenofovir-Emtricitabine With Atazanavir-Ritonavir or Efavirenz: ACTG
Study A5224s.
McComsey GA, Kitch D, Sax
PE,
et al
Clin Infect Dis.
2011 Jul;53(2):185-96.
Abstract
Bone Mineral Density and Fractures in Antiretroviral-Naive Persons
Randomized to Receive
Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine
Along With Efavirenz or
Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of
ACTG A5202.
McComsey GA, Kitch D, Daar ES,
et
al
J Infect Dis.
2011 Jun;203(12):1791-801.
Abstract
Open-label randomized multicenter selection study of once daily
antiretroviral treatment regimen
comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose
abacavir and Lamivudine.
Honda M, Ishisaka M, Ishizuka N,
et
al
Intern Med.
2011;50(7):699-705.
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
Pharmacokinetics and acceptability of once- versus twice-daily
lamivudine and
abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
Musiime V, Kendall L, Bakeera-Kitaka S, et al
Antivir Ther.
2010;15(8):1115-1124.
Abstract |
A WEEK-IN-REVIEW
FEATURED REPORT
Comparison of Changes in Bone Density and Turnover with
Abacavir-Lamivudine versus
Tenofovir-Emtricitabine in HIV-Infected Adults: 48-Week Results from
the ASSERT Study.
Stellbrink HJ, Orkin C, Arribas JR, et al
Clin Infect Dis. 2010 Sep
Abstract |
A
WEEK-IN-REVIEW FEATURED REPORT
Randomized Comparison of Renal Effects, Efficacy, and Safety With
Once-Daily
Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With
Efavirenz,
in Antiretroviral-Naive, HIV-1-Infected Adults: 48-Week Results From
the ASSERT
Study.
Post FA, Moyle GJ, Stellbrink HJ, et al
J Acquir Immune Defic Syndr. 2010 Apr 24
Abstract
Abacavir-Lamivudine versus Tenofovir-Emtricitabine for Initial HIV-1 Therapy.
Sax PE, Tierney C, Collier AC,
et al
N Engl J Med. 2009 Dec
3;361(23):2230-2240.
Abstract |
Abacavir and lamivudine combination.
Somboonwit C, Kurtyka D, Paula Velez A.
Expert Opin Drug Metab Toxicol.
2009 Dec;5(12):1599-606.
Abstract |
Simplification of Antiretroviral Therapy with Tenofovir-Emtricitabine or
Abacavir-Lamivudine:
A Randomized, 96-Week Trial.
Martin A, Bloch M, Amin J, et al
Clin Infect Dis.
2009 Nov 15;49(10):1591-1601
Abstract |
A WEEK-IN-REVIEW FEATURED REPORT
Randomized, double-blind, placebo-matched, multicenter trial of
abacavir/lamivudine or
tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV
treatment.
Smith KY, Patel P, Fine D, et al
AIDS.
2009 Jun 17.
Abstract |
A WEEK-IN-REVIEW FEATURED REPORT
Virologic response and safety of the abacavir/lamivudine fixed-dose
formulation as part of highly active
antiretroviral therapy: analyses of six clinical studies.
Ha B, Liao QM, Dix LP, Pappa KA.
HIV Clin Trials.
2009 Mar-Apr;10(2):65-75
Abstract |
A Simplification Trial Switching From Nucleoside Reverse Transcriptase
Inhibitors to Once-Daily
Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in
HIV-1-Infected Patients With Virological
Suppression.
Martínez E, Arranz JA, Podzamczer D,
et al
J Acquir Immune Defic Syndr.
2009 Apr 24.
Abstract |
Two novel fixed formulations of nucleoside analogues
(tenofovir-emtricitabine, and
abacavir-lamivudine).
Prospective, open study on clinical practice and therapeutic
perspectives, in patients naïve and in
subjects pre-treated with antiretrovirals
Manfredi R, Calza L.
Recenti Prog Med.
2008 Oct;99(10):492-501
Abstract |
Switching from twice-daily abacavir and lamivudine to the
once-daily fixed-dose combination tablet of
abacavir and lamivudine improves patient adherence and
satisfaction with therapy.
Maitland D, Jackson A, Osorio J, et al
HIV Med. 2008 Oct;9(8):667-72.
Abstract
|
A WEEK IN REVIEW FEATURED REPORT
Short-term Safety and Tolerability of a Once-Daily Fixed-Dose
Abacavir-Lamivudine Combination
versus Twice-Daily Dosing of Abacavir and Lamivudine as Separate Components:
Findings from the
ALOHA Study.
Cohen CJ, Kubota M, Brachman PS, et al
Pharmacotherapy. 2008 Mar;28(3):314-322.
Abstract
|
Abacavir plus Lamivudine: A Review of their Combined Use in the Management
of HIV Infection.
Dando TM, Scott LJ.
Drugs.
2005;65(2):285-302
Abstract |
Documents
identified with this icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader
Abstract
ARV
Drugs Main Page
Main New/Newsworthy